4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 9,810 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 9,810 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the completion of the sale, the insider owned 8,617 shares in the company, valued at $103,404. This represents a 53.24% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

4D Molecular Therapeutics Stock Down 0.9%

Shares of 4D Molecular Therapeutics stock opened at $11.52 on Friday. 4D Molecular Therapeutics, Inc. has a 12-month low of $3.68 and a 12-month high of $12.34. The stock has a market capitalization of $602.27 million, a P/E ratio of -4.48 and a beta of 2.75. The company has a 50-day simple moving average of $9.54 and a 200 day simple moving average of $9.14.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). The firm had revenue of $3.05 million for the quarter, compared to the consensus estimate of $2.59 million. 4D Molecular Therapeutics had a negative return on equity of 36.83% and a negative net margin of 182.34%. On average, equities analysts anticipate that 4D Molecular Therapeutics, Inc. will post -4.14 earnings per share for the current year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Bank of America Corp DE lifted its stake in shares of 4D Molecular Therapeutics by 17.0% during the first quarter. Bank of America Corp DE now owns 974,173 shares of the company’s stock valued at $9,070,000 after acquiring an additional 141,582 shares during the period. Janus Henderson Group PLC increased its position in 4D Molecular Therapeutics by 13.2% in the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock worth $48,868,000 after purchasing an additional 611,276 shares during the period. Exome Asset Management LLC bought a new stake in 4D Molecular Therapeutics during the 1st quarter worth about $1,216,000. Renaissance Technologies LLC raised its holdings in 4D Molecular Therapeutics by 12.7% during the 1st quarter. Renaissance Technologies LLC now owns 578,265 shares of the company’s stock worth $5,384,000 after purchasing an additional 65,365 shares during the last quarter. Finally, Sei Investments Co. lifted its position in 4D Molecular Therapeutics by 8.9% during the 1st quarter. Sei Investments Co. now owns 12,862 shares of the company’s stock valued at $120,000 after purchasing an additional 1,050 shares during the period. Institutional investors own 99.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on FDMT. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Monday, April 20th. HC Wainwright restated a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. Jefferies Financial Group reiterated a “buy” rating and set a $21.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Royal Bank Of Canada raised their price objective on shares of 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $29.88.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.